ArticleVaccines2026
Mpox-Related Knowledge, Risk Perception, and Vaccination Willingness Among University Students in Aktobe, Kazakhstan: A Cross-Sectional Study.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMpox is a re-emerging viral zoonotic disease that remains relevant for public health preparedness, risk communication, and vaccination literacy. University students are an important population for infectious disease communication because they are socially active, digitally connected, and may act as knowledge multipliers. This study assessed Mpox-related knowledge, risk perception, preventive practices, and willingness to receive Mpox vaccination among university students in Aktobe, Kazakhstan, and identified independent predictors of adequate knowledge and vaccination willingness.
methodsA cross-sectional questionnaire-based survey was conducted among students from three universities. The questionnaire collected socio-demographic characteristics, Mpox-related knowledge, information sources, attitudes, preventive practices, perceived risk, and vaccination willingness. Knowledge was summarized using a three-item score; adequate knowledge was defined as a score of at least 2 out of 3. Two multivariable logistic regression models were fitted: one for adequate Mpox-related knowledge and one for willingness to receive Mpox vaccination.
resultsThe final descriptive dataset included 482 respondents. Most participants were female (66.8%), from urban areas (80.5%), and aged 17-18 years (61.6%). Only 217 students (45.0%) had previously heard about Mpox, 193 (40.0%) correctly identified rash as the main symptom, and 179 (37.1%) knew that vaccination against Mpox exists. Adequate knowledge was observed in 201 students (41.7%), while only 150 students (31.1%) were willing to receive Mpox vaccination. In the multivariable model, adequate knowledge was independently associated with studying at Marat Ospanov West Kazakhstan Medical University (aOR = 5.66; 95% CI: 2.95-10.84), use of medical websites as an information source (aOR = 1.71; 95% CI: 1.09-2.69), and following infectious disease news (aOR = 2.81; 95% CI: 1.76-4.48). Vaccination willingness was independently associated with considering Mpox a dangerous infectious disease (aOR = 2.04; 95% CI: 1.11-3.77) and perceiving Mpox as a threat to Kazakhstan (aOR = 2.16; 95% CI: 1.30-3.59).
conclusionsMpox-related knowledge among university students in Aktobe was limited, while vaccination willingness remained low despite moderate perceived risk. Reliable information exposure improved knowledge, whereas vaccination willingness was more strongly associated with perceived disease threat. These findings support university-based health literacy, vaccine literacy, and risk communication interventions aimed at improving preparedness for emerging infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.